Drugs that contain Lurasidone Hydrochloride

1. List of Latuda drug patents

LATUDA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE45573 SUNOVION PHARMS INC Process for producing imide compound
Jun, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174975 SUNOVION PHARMS INC Remedy for integration dysfunction syndrome
Feb, 2024

(8 months from now)

US9815827 SUNOVION PHARMS INC Agent for treatment of schizophrenia
Feb, 2024

(8 months from now)

US9174975

(Pediatric)

SUNOVION PHARMS INC Remedy for integration dysfunction syndrome
Aug, 2024

(1 year, 2 months from now)

USRE45573

(Pediatric)

SUNOVION PHARMS INC Process for producing imide compound
Dec, 2025

(2 years from now)

US8883794 SUNOVION PHARMS INC Pharmaceutical composition
May, 2026

(2 years from now)

US9555027 SUNOVION PHARMS INC Pharmaceutical composition
May, 2026

(2 years from now)

US9907794 SUNOVION PHARMS INC Pharmaceutical composition
May, 2026

(2 years from now)

US8729085 SUNOVION PHARMS INC Pharmaceutical composition
May, 2026

(2 years from now)

US9907794

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition
Nov, 2026

(3 years from now)

US8883794

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition
Nov, 2026

(3 years from now)

US8729085

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition
Nov, 2026

(3 years from now)

US9827242 SUNOVION PHARMS INC Method of treatment for mental disorders
May, 2031

(7 years from now)

US9259423 SUNOVION PHARMS INC Method of treatment for mental disorders
May, 2031

(7 years from now)

US9259423

(Pediatric)

SUNOVION PHARMS INC Method of treatment for mental disorders
Nov, 2031

(8 years from now)

Market Authorisation Date: 28 October, 2010

Treatment: Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia; Treatment of major depressive episodes associated with bipolar i disorder; Treatment of ...

Dosage: TABLET;ORAL

How can I launch a generic of LATUDA before it's patent expiration?
More Information on Dosage

LATUDA family patents

16

United States

11

Japan

6

European Union

4

Spain

3

China

2

Canada

2

Korea, Republic of

2

Brazil

2

Denmark

2

Australia

1

Poland

1

Slovenia

1

Luxembourg

1

Hong Kong

1

Taiwan

1

Germany

1

Netherlands

1

Hungary

1

Mexico

1

Austria

1

Portugal

1

Russia

1

Cyprus

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in